Bilateral same-session intravitreal injections of antivascular endothelial growth factors

International Journal of Ophthalmology

Volumn 7, Issue 6, 2014, Pages 1017-1021

  Abu Yaghi, Nakhleh E ^a   Shokry, Ahmed N ^a   Abu Sbeit, Rami H ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Age related macular degeneration; Anti vascular endothelial growth factor; Diabetic macular edema; Endophthalmitis; Visual acuity

Indexed keywords

EID: 84925443310     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2014.06.20     Document Type: Article

References (25)

1. Bakri SJ, Risco M, Edwards AO, Pulido JS. Bilateral simultaneous intravitreal injections in the office setting. Am J Ophthalmol 2009;148(1): 66-69.
2. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 2009;54(3):372-400.
3. Krispel C, Rodrigues M, Xin X, Sodhi A. Ranibizumab in diabetic macular edema. World J Diabetes 2013;4(6):310-318.
4. Fung AE, Palanki R, Bakri SJ, Depperschmidt E, Gibson A. Applying the CONSORT and STROBE statements to evaluate the reporting quality of neovascular age-related macular degeneration studies. Ophthalmology 2009;116(2):286-296.
5. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M. An optical coherence tomography-guided, variable-dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143(4):566-583.
6. Stewart MW. Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmol 2013;7:1257-1267.
7. Huang P, Niu W, Ni Z, Wang R, Sun X. A meta-analysis of anti-vascular endothelial growth factor remedy for macular edema secondary to central retinal vein occlusion. PLoS One 2013;8(12):e82454.
8. Tan MH, McAllister IL, Gillies ME, Verma N, Banerjee G, Smithies LA, Wong WL, Wong TY. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion. Am J Ophthalmol 2014;157(1):237-247.
9. Abu-Yaghi NE, Bakri SJ. The use of antivascular endothelial growth factor agents in the perioperative period in diabetic vitrectomy. Middle East Afr J Ophthalmol 2012;19(1):83-87.
10. Green-Simms AE, Ekdawi NS, Bakri SJ. Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol 2011;151(2):329-332.
11. Nuzzi R, Tridico F. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study. Semin Ophthalmol 2013 [Epub ahead of print].
12. Pershing S, Bakri SJ, Moshfeghi DM. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina 2013;44(5): 460-464.
13. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009;18(9):658-661.
14. Semoun O, Blumen-Ohana E, de Preobrajensky N, Nordmann JP. Acute angle-closure glaucoma complicating an intravitreal injection of bevacizumab. J Fr Ophtalmol 2009;32(1):58.e1-4.
15. Matsuyama K, Ogata N, Matsuoka M, Wada M, Nishimura T, Takahashi K. Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes. J Ocul Pharmacol Ther 2011;27(4):379-383.
16. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364 (20): 1897-1908.
17. Davis RP, Schefler AC, Murray TG. Concomitant bilateral intravitreal anti-VEGF injections for the treatment of exudative age-related macular degeneration. Clin Ophthalmol 2010;4:703-707.
18. Lima LH, Zweifel SA, Engelbert M, Sorenson JA, Slakter JS, Cooney MJ, Klancnik JM, Yannuzzi LA, Freund KB. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina 2009;29(9):1213-1217.
19. Woo SJ, Han JM, Ahn J, Heo JW, Yu HG, Chung H, Song J, Park KU, Park KH. Bilateral same-day intravitreal injections using a single vial and molecular bacterial screening for safety surveillance. Retina 2012;32(4): 667-671.
20. Wang D, Choi KS, Lee SJ. Serum concentration of vascular endothelial growth factor after bilateral intravitreal injection of bevacizumab. Korean J Ophthalmol 2014;28(1):32-38.
21. Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, Heier JS, Hollands H, Sharma S. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28 (10): 1395-1399.
22. Diago T, McCannel CA, Bakri SJ, Pulido JS, Edwards AO, Pach JM. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina 2009;29(5):601-605.
23. Marticorena J, Romano V, Gomez-Ulla F. Sterile endophthalmitis after intravitreal injections. Mediators Inflamm 2012;2012:928123.
24. Roth DB, Flynn HW Jr. Distinguishing between infectious and noninfectious endophthalmitis after intravitreal triamcinolone injection. Am J Ophthalmol 2008;146:346-347.
25. Mahajan VB, Elkins KA, Russell SR, Boldt HC, Gehrs KM, Weingeist TA, Stone EM, Abramoff MD, Liu D, Folk JC. Bilateral intravitreal injection of antivascular endothelial growth factor therapy. Retina 2011;31(1):31-35.